89bio (Nasdaq:ETNB) - Stock Price, News & Analysis

ETNB Stock Overview

A clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.

About the company

ETNB fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 81.76% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

89bio, Inc. Competitors

Silence Therapeutics

NasdaqGM:SLN

US$855.0m

Applied Therapeutics

NasdaqGM:APLT

US$884.3m

Tango Therapeutics

NasdaqGM:TNGX

US$889.3m

Perspective Therapeutics

NYSEAM:CATX

US$892.1m

Price History & Performance

Summary of all time highs, changes and price drops for 89bio
Historical stock prices
Current Share Price	US$8.19
52 Week High	US$16.63
52 Week Low	US$6.58
Beta	1.0
11 Month Change	-7.51%
3 Month Change	4.20%
1 Year Change	-46.22%
33 Year Change	-60.57%
5 Year Change	n/a
Change since IPO	-60.62%

89bio: Bullish In Light Of Further MOA Being Established By Peer

Aug 07

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

May 23

Recent updates

Shareholder Returns

	ETNB	US Biotechs	US Market
7D	-0.2%	-1.3%	1.2%
1Y	-46.2%	23.2%	30.2%

Return vs Industry: ETNB underperformed the US Biotechs industry which returned 23.2% over the past year.

Return vs Market: ETNB underperformed the US Market which returned 30.2% over the past year.

Price Volatility

Is ETNB's price volatile compared to industry and market?
ETNB volatility
ETNB Average Weekly Movement	8.5%
Biotechs Industry Average Movement	10.2%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ETNB's share price has been volatile over the past 3 months.

Volatility Over Time: ETNB's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2018	70	Rohan Palekar	www.89bio.com

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

89bio, Inc. Fundamentals Summary

How do 89bio's earnings and revenue compare to its market cap?
ETNB fundamental statistics
Market cap	US$867.40m
Earnings (TTM)	-US$174.61m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-5.0x

P/E Ratio

Is ETNB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ETNB income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$174.61m
Earnings	-US$174.61m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.65
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	4.9%

How did ETNB perform over the long term?

See historical performance and comparison

ETNB Stock Overview

Rewards

Risk Analysis

89bio, Inc. Competitors

NasdaqGM:SLN

US$855.0m

NasdaqGM:APLT

US$884.3m

NasdaqGM:TNGX

US$889.3m

NYSEAM:CATX

US$892.1m

Price History & Performance

Recent News & Updates

89bio, Inc. Appoints Teresa Perney as Chief Regulatory and Quality Officer

89bio: Bullish In Light Of Further MOA Being Established By Peer

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Growth Index

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (Mash) Patients with Compensated Cirrhosis

Recent updates

89bio, Inc. Appoints Teresa Perney as Chief Regulatory and Quality Officer

89bio: Bullish In Light Of Further MOA Being Established By Peer

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Growth Index

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (Mash) Patients with Compensated Cirrhosis

89bio, Inc., Annual General Meeting, May 29, 2024

89bio, Inc. Appoints Martin Babler to Its Board of Directors

89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis (Mash), Formerly Known as Nonalcoholic Steatohepatitis

89bio, Inc. announced delayed annual 10-K filing

CEO & Director notifies of intention to sell stock

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

89bio, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

89bio, Inc. Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89Bio Announces Additional Data from the Enliven Phase 2B Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis

Price target decreased by 9.4% to US$33.44

New minor risk - Share price stability

Price target increased by 7.8% to US$37.44

89bio, Inc. Announces Data from the Phase 2B Enliven Trial Evaluating Treatment with Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia

Insider notifies of intention to sell stock

Consensus EPS estimates upgraded to US$2.01 loss

Chief Financial Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Price target increased by 34% to US$33.75

Independent Director exercised options and sold US$92k worth of stock

Chief Financial Officer notifies of intention to sell stock

Price target increased to US$24.63

89bio, Inc. Announces Publication of Results of Phase 1B/2A Study of Pegozafermin for the Treatment of NASH in the Lancet Gastroenterology & Hepatology

Consensus forecasts updated

89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting(R) 2022

89bio Still Has A Chance As NASH Race Heats Up

Consensus forecasts updated

CEO & Director exercised options to buy US$478k worth of stock.

89bio, Inc. Presents Positive Results from Entrigue Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia At European Society of Cardiology Congress 2022

89Bio, Inc. Completes Enrollment in Enliven, the Phase 2B Trial of Pegozafermin for the Treatment of NASH

89bio completes enrollment in phase 2 trial for NASH treatment

89Bio rallies on Deep Track Capital disclosing 10% stake

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Index

Price target decreased to US$45.67

89bio, Inc., Annual General Meeting, Jun 01, 2022

Price target decreased to US$45.67

89bio, Inc. Appoints Edward Morrow Atkinson to the Board

CEO & Director recently bought US$53k worth of stock

89Bio, Inc. Announces Positive Topline Results from an Open-Label Expansion Cohort of 20 Patients in the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$102k worth of stock

COO & Chief Business Officer exercised options and sold US$109k worth of stock

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$114k worth of stock

Independent Director Anat Naschitz has left the company

89Bio Completes Target Enrollment in Histology Cohort to Evaluate Bio89-100 for the Treatment of Nash

Price target decreased to US$52.50